|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STAG2 |
Gene summary for STAG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STAG2 | Gene ID | 10735 |
| Gene name | stromal antigen 2 | |
| Gene Alias | HPE13 | |
| Cytomap | Xq25 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q6MZP3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10735 | STAG2 | LZE4T | Human | Esophagus | ESCC | 2.34e-11 | 3.42e-01 | 0.0811 |
| 10735 | STAG2 | LZE7T | Human | Esophagus | ESCC | 9.73e-07 | 8.43e-01 | 0.0667 |
| 10735 | STAG2 | LZE8T | Human | Esophagus | ESCC | 4.64e-04 | 1.09e-01 | 0.067 |
| 10735 | STAG2 | LZE20T | Human | Esophagus | ESCC | 7.50e-03 | 1.52e-01 | 0.0662 |
| 10735 | STAG2 | LZE24T | Human | Esophagus | ESCC | 2.46e-21 | 7.84e-01 | 0.0596 |
| 10735 | STAG2 | LZE6T | Human | Esophagus | ESCC | 4.85e-07 | 9.76e-02 | 0.0845 |
| 10735 | STAG2 | P1T-E | Human | Esophagus | ESCC | 2.85e-03 | 5.73e-01 | 0.0875 |
| 10735 | STAG2 | P2T-E | Human | Esophagus | ESCC | 4.42e-32 | 6.91e-01 | 0.1177 |
| 10735 | STAG2 | P4T-E | Human | Esophagus | ESCC | 1.38e-14 | 5.31e-01 | 0.1323 |
| 10735 | STAG2 | P5T-E | Human | Esophagus | ESCC | 1.92e-14 | 2.49e-01 | 0.1327 |
| 10735 | STAG2 | P8T-E | Human | Esophagus | ESCC | 1.61e-24 | 5.36e-01 | 0.0889 |
| 10735 | STAG2 | P9T-E | Human | Esophagus | ESCC | 3.34e-18 | 4.56e-01 | 0.1131 |
| 10735 | STAG2 | P10T-E | Human | Esophagus | ESCC | 4.65e-54 | 1.21e+00 | 0.116 |
| 10735 | STAG2 | P11T-E | Human | Esophagus | ESCC | 3.33e-11 | 3.45e-01 | 0.1426 |
| 10735 | STAG2 | P12T-E | Human | Esophagus | ESCC | 1.45e-18 | 4.52e-01 | 0.1122 |
| 10735 | STAG2 | P15T-E | Human | Esophagus | ESCC | 1.57e-17 | 5.05e-01 | 0.1149 |
| 10735 | STAG2 | P16T-E | Human | Esophagus | ESCC | 8.72e-19 | 2.77e-01 | 0.1153 |
| 10735 | STAG2 | P17T-E | Human | Esophagus | ESCC | 2.04e-06 | 1.59e-01 | 0.1278 |
| 10735 | STAG2 | P19T-E | Human | Esophagus | ESCC | 3.40e-03 | 2.90e-01 | 0.1662 |
| 10735 | STAG2 | P20T-E | Human | Esophagus | ESCC | 1.02e-16 | 3.38e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:00512256 | Esophagus | ESCC | spindle assembly | 85/8552 | 117/18723 | 2.72e-09 | 5.98e-08 | 85 |
| GO:009030715 | Esophagus | ESCC | mitotic spindle assembly | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:00070627 | Esophagus | ESCC | sister chromatid cohesion | 40/8552 | 62/18723 | 2.14e-03 | 9.54e-03 | 40 |
| GO:01400142 | Liver | Cirrhotic | mitotic nuclear division | 97/4634 | 287/18723 | 3.32e-04 | 2.87e-03 | 97 |
| GO:00070522 | Liver | Cirrhotic | mitotic spindle organization | 46/4634 | 120/18723 | 6.56e-04 | 4.98e-03 | 46 |
| GO:00903073 | Liver | Cirrhotic | mitotic spindle assembly | 27/4634 | 65/18723 | 2.14e-03 | 1.32e-02 | 27 |
| GO:19028502 | Liver | Cirrhotic | microtubule cytoskeleton organization involved in mitosis | 52/4634 | 147/18723 | 2.52e-03 | 1.51e-02 | 52 |
| GO:00070514 | Liver | Cirrhotic | spindle organization | 62/4634 | 184/18723 | 3.88e-03 | 2.10e-02 | 62 |
| GO:00512252 | Liver | Cirrhotic | spindle assembly | 41/4634 | 117/18723 | 8.08e-03 | 3.79e-02 | 41 |
| GO:0000819 | Liver | Cirrhotic | sister chromatid segregation | 65/4634 | 202/18723 | 1.01e-02 | 4.52e-02 | 65 |
| GO:014001411 | Liver | HCC | mitotic nuclear division | 174/7958 | 287/18723 | 3.74e-10 | 1.23e-08 | 174 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411041 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
| hsa0411051 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
| hsa0411061 | Oral cavity | NEOLP | Cell cycle | 37/1112 | 157/8465 | 2.29e-04 | 1.58e-03 | 9.95e-04 | 37 |
| hsa0411071 | Oral cavity | NEOLP | Cell cycle | 37/1112 | 157/8465 | 2.29e-04 | 1.58e-03 | 9.95e-04 | 37 |
| hsa041107 | Prostate | BPH | Cell cycle | 49/1718 | 157/8465 | 7.39e-04 | 3.59e-03 | 2.22e-03 | 49 |
| hsa0411014 | Prostate | BPH | Cell cycle | 49/1718 | 157/8465 | 7.39e-04 | 3.59e-03 | 2.22e-03 | 49 |
| hsa0411021 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
| hsa0411031 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STAG2 | SNV | Missense_Mutation | novel | c.1222N>A | p.Glu408Lys | p.E408K | Q8N3U4 | protein_coding | tolerated(0.39) | possibly_damaging(0.498) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| STAG2 | SNV | Missense_Mutation | c.2093A>G | p.His698Arg | p.H698R | Q8N3U4 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| STAG2 | SNV | Missense_Mutation | novel | c.1416G>T | p.Glu472Asp | p.E472D | Q8N3U4 | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| STAG2 | SNV | Missense_Mutation | c.1234N>T | p.Asn412Tyr | p.N412Y | Q8N3U4 | protein_coding | tolerated(0.1) | possibly_damaging(0.568) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STAG2 | SNV | Missense_Mutation | novel | c.206G>A | p.Arg69Gln | p.R69Q | Q8N3U4 | protein_coding | tolerated(0.24) | benign(0.34) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STAG2 | SNV | Missense_Mutation | c.1456G>A | p.Asp486Asn | p.D486N | Q8N3U4 | protein_coding | deleterious(0) | possibly_damaging(0.777) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| STAG2 | SNV | Missense_Mutation | c.3385C>T | p.Pro1129Ser | p.P1129S | Q8N3U4 | protein_coding | tolerated(0.37) | benign(0.013) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| STAG2 | SNV | Missense_Mutation | c.1678A>T | p.Arg560Trp | p.R560W | Q8N3U4 | protein_coding | deleterious(0.01) | possibly_damaging(0.908) | TCGA-D8-A1X5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| STAG2 | SNV | Missense_Mutation | c.1712T>C | p.Leu571Pro | p.L571P | Q8N3U4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STAG2 | SNV | Missense_Mutation | c.832C>G | p.Gln278Glu | p.Q278E | Q8N3U4 | protein_coding | tolerated(0.06) | benign(0.415) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Trametinib | TRAMETINIB | 27500726 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Camptothecin | CAMPTOTHECIN | 21852505,24356817 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Dabrafenib | DABRAFENIB | 27500726 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Temozolomide | TEMOZOLOMIDE | 21852505,24356817 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Olaparib | OLAPARIB | 21852505,24356817 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | VEMURAFENIB | VEMURAFENIB | 27500726 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Vemurafenib | VEMURAFENIB | 27500726 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Rucaparib | RUCAPARIB | 21852505,24356817 | |
| 10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | Veliparib | VELIPARIB | 21852505,24356817 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |